LEARN HOW WE APPROACH REGENERATIVE CARDIAC MEDICINE OF TOMORROW
The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardia tissue after an injury.
After receiving FDA and EMA approval, Recardio is currently initiating its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
Recardio’s global and pivotal Phase 3 HEAL-MI study is starting in 2024 and evaluating the clinical outcomes of dutogliptin as an adjunct treatment for patients with acute myocardial infarction.
Being located in the US and Europe, we are committed to develop the regenerative therapies of the future. To support our clinical development, we are continuously looking to expand our team.